株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

急性骨髄性白血病(AML)治療の世界市場

Acute Myeloid Leukemia (AML) Therapeutics

発行 Global Industry Analysts, Inc. 商品コード 248882
出版日 ページ情報 英文 486 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
急性骨髄性白血病(AML)治療の世界市場 Acute Myeloid Leukemia (AML) Therapeutics
出版日: 2012年07月01日 ページ情報: 英文 486 Pages
概要

当レポートでは、急性骨髄性白血病(AML)治療の世界市場を取り上げ、米国、日本、欧州、およびその他の地域など、地域ごとの個別分析を行うとともに、過去の実績/推定および予測を提供し、主要企業およびニッチ企業68社のプロフィールをまとめるなど、概略以下の構成でお届けします。

第1章 イントロダクション、調査方法、製品定義

  • 調査の信頼性とレポートの制約
  • 免責事項
  • データの解釈とレポートのレベル
    • 定量技法および分析法
  • 製品の定義と調査範囲

第2章 エグゼクティブサマリー

  • 世界市場の概要
    • 急性骨髄性白血病(AML):圧倒的に年配者に多い疾病
    • 市場の見通し
    • 特筆すべき成長促進要因/動向および懸案事項
    • 高齢人口の拡大:主要な促進要因
    • AML市場を特徴づける未対応の高いニーズ
    • 早急な対応を要する高い再発率
    • AML治療において拡大する細胞遺伝学の影響
    • オーファンドラッグ(希少疾病用薬)および優先審査指定がAML治療を推進
    • オーファンドラッグ/優先審査指定を受けた主要なAML薬剤
    • AML治療における堅固なパイプラインが市場成長を促進
    • フェーズIII治験中の主要なAML薬剤
    • フェーズII治験中の主要なAML薬剤
    • フェーズI治験中の主要なAML薬剤
    • 小児AML:注目が拡大
    • 将来における改良がHSCTの導入増を支援
    • 減量強度同種移植:可能性を秘めながらも活用されていない手順
    • 新たな組み合わせ療法が地歩を築く
    • ターゲット療法:衰えぬ勢い
    • 薬剤ターゲットの失敗が成長見通しを抑制
      • 足跡を残せなかった主なAML薬剤
    • Mylotargは2度目のチャンスで成功するか
    • エピジェネティック(後成的)治療: AMLの新たな治療法
    • AML治療においてワクチンは大躍進となるか
    • APL治療の成功は他の種類のAML複製できるか
  • 主要な認可済みおよび潜在的なAML薬剤
  • 急性骨髄性白血病:疾病、疫学、病因学、症状、および診断
    • 骨髄ならびに血球の理解
    • 血球
    • 白血球
    • 赤血球
    • 血小板
    • 癌:死に至る病
    • 白血病:骨髄の病気
    • 急性白血病
    • 慢性白血病
    • 歴史
    • 癌発生率:新たな症例に関する統計
    • 急性骨髄性白血病
    • 急性骨髄性白血病(AML)の種類
    • FABによるAMLの分類
    • WHOによるAMLの分類
    • 非定型もしくは混合型の急性白血病
    • 疫学
    • AMLの病因学
    • 化学物質
    • 放射線
    • 喫煙
    • 既往血液疾患
    • 遺伝的要素
    • AMLの症状
    • あざまたは出血の増加
    • 繰り返されるもしくは高頻度の感染
    • 貧血
    • AMLの診断
    • 総血球数
    • 骨髄検査
    • その他の検査
  • 治療の概要
    • 化学療法:AMLの第一選択治療
    • 寛解後療法または地固め療法
    • 造血幹細胞移植
    • 再発AMLの治療
    • 維持管理
    • AML治療における副作用
    • 骨髄、血小板、赤血球、および白血球への影響
    • その他の一般的な副作用
    • AML医療を補完する療法
  • FDAおよびその他規制認可
  • 主要な治験
  • 業界における最近の動き
  • 主要な企業
    • Ambit Biosciences Inc.(米国)
    • Aprea AB(スウェーデン)
    • アステラス製薬(日本)
    • Astex Pharmaceuticals, Inc.(米国)
    • Bio-Path Holdings, Inc.(米国)
    • BioSante Pharmaceuticals, Inc.(米国)
    • Celator Pharmaceuticals, Inc.(米国)
    • Celgene Corp.(米国)
    • Clavis Pharma ASA(ノルウェー)
    • Cyclacel Pharmaceuticals, Inc.(米国)
    • EpiCept Corp.(米国)
    • Genzyme Corporation(米国)
    • Lorus Therapeutics, Inc.(カナダ)
    • Novartis AG(スイス)
    • Onconova Therapeutics, Inc.(米国)
    • Sunesis Pharmaceuticals, Inc.(米国)
  • 世界市場の展望

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • その他欧州
  • その他の地域

第4章 競合情勢

目次
Product Code: MCP-6847

This report analyzes the worldwide markets for Acute Myeloid Leukemia (AML) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. European market for AML Therapeutics is further analyzed by the following countries/regions - France, Germany, Italy, UK, and Rest of Europe. Annual estimates and forecasts are provided for the period 2009 through 2018. The report profiles 68 companies including many key and niche players such as Ambit Biosciences Inc., Aprea AB, Astellas Pharma Inc., Astex Pharmaceuticals, Inc., Bio-Path Holdings, Inc., BioSante Pharmaceuticals, Inc., Celator Pharmaceuticals, Inc., Celgene Corp., Clavis Pharma ASA, Cyclacel Pharmaceuticals, Inc., EpiCept Corp., Genzyme Corporation, Lorus Therapeutics, Inc., Novartis AG, Onconova Therapeutics, Inc., and Sunesis Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW

  • Acute Myeloid Leukemia (AML): A Disease, Predominantly of the Elderly
  • Market Outlook
  • Noteworthy Growth Drivers/Trends and Issues
  • Growing Aging Population - A Major Driver
    • Opportunity Indicator
    • Table 1: 2011 Global Population Statistics for the 65+ Age Group
  • High Unmet Needs Characterize the AML Market
  • High Relapse Rates Demand Immediate Attention
  • Influence of Cytogentics Increasing in AML Treatment
  • Orphan Drug and Fast Track Designations Provide Impetus for AML Therapeutics
  • Select AML Drugs Awarded Orphan Drug/Fast Track Designation
  • Robust Pipeline of AML Therapeutics to Spur Market Growth
  • Select AML Drugs in Phase III Clinical Trials
  • Select AML Drugs in Phase II Clinical Trials
  • Select AML Drugs in Phase I Clinical Trials
  • Pediatric AML: Focus Increasing
  • Future Refinements to aid in Increasing Adoption of HSCT
  • Reduced-Intensity Allogeneic Transplant: An Underutilized Procedure with Potential
  • New Combination Therapies Gaining Ground
  • Targeted Therapies: Momentum Continues
  • Failed Drug Targets Slowdown the Growth Prospects
    • Select AML Drugs Failing to Make a Mark
  • Will the Second Chance Hold Good for Mylotarg?
  • Epigenetic Therapeutics: New Treatment on the Block for AML
  • Will Vaccines Prove to be a Breakthrough for AML Treatment?
  • Can the Success of APL Treatments be Duplicated for Other Sub Types of AML?

2. SELECT APPROVED AND POTENTIAL AML DRUGS

  • Ceplene and Vidaza - The Approved Drugs
  • Ceplene (EpiCept)
  • VIDAZA (Celgene Corp)
  • A Review of Select Aml Drugs under Development
  • AKN-028 (Akinion Pharmaceuticals)
  • ALT-801 (Altor Bioscience Corporation)
  • Quizartinib (Ambit/Astellas)
  • APR-246 (Aprea AB)
  • Dacogen (Astex Pharmaceuticals/Eisai)
  • SGI-110 (Astex Pharmaceuticals, Inc.)
  • BP-100-1.01 (Liposomal Grb-2) (Bio-Path Holdings, Inc)
  • GVAX AML (BioSante Pharmaceuticals, Inc.)
  • Volasertib or BI 6727 (Boehringer Ingelheim GmbH)
  • CPX-351 (Celator Pharmaceuticals, Inc)
  • Tosedostat (formerly CHR-2797) (Chroma Therapeutics Ltd)
  • Elacytarabine (CP-4055) (Clavis Pharma ASA)
  • Sapacitabine (Cyclacel)
  • Aezea (Cenersen) (Eleos, Inc)
  • Clolar (Genzyme/Sanofi)
  • IPH2102 (Innate Pharma S.A)
  • LOR-2040 (Lorus Therapeutics, Inc.)
  • Midostaurin (Novartis)
  • Panobinostat (Novartis)
  • PR104 (Proacta, Inc.)
  • SB1317 (S*BIO Pte Ltd)
  • Vosaroxin (Sunesis Pharmaceuticals, Inc.)
  • ONCOHIST (SymbioTec GmbH)
  • Elesclomol (Synta Pharmaceuticals, Inc.)
  • MLN8237 (Takeda Pharmaceuticals Co., Ltd)

3. ACUTE MYELOID LEUKEMIA - THE DISEASE, EPIMEDIOLOGY, ETIOLOGY, SYMPTOMS, AND DIAGNOSIS

  • Understanding the Bone Marrow, and the Blood Cells
  • Blood Cells
  • White Cells
  • Red Cells
  • Platelets
  • Cancer - The Deadly Disease
  • Leukemia - A Disease of the Bone Marrow
  • Acute Leukemia
  • Chronic Leukemia
  • History
  • Cancer Incidence - Statistics on New Cases
    • Table 2: Global Cancer Incidence by Region: 2009 (includes corresponding Graph/Chart)
    • Table 3: Global Cancer Incidence by Income Group: 2009 (includes corresponding Graph/Chart)
    • Table 4: Cancer Incidence in Upper Middle Income Countries by Site: 2009 (includes corresponding Graph/Chart)
    • Table 5: Cancer Incidence in Lower Middle Income Countries by Site: 2009 (includes corresponding Graph/Chart)
    • Table 6: Cancer Incidence in High Income Countries by Site: 2009 (includes corresponding Graph/Chart)
  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia (AML) Types
  • The FAB Classification of AML
  • WHO AML Classification
    • AML with Certain Genetic Abnormalities
    • AML with Multilineage Dysplasia
    • AML Related to Previous Chemotherapy or Radiation
      • AML Not Otherwise Specified
    • Undifferentiated or Biphenotypic Acute Leukemias
  • Epidemiology
  • Etiology of AML
  • Chemicals
  • Radiation
  • Smoking
  • Pre-existing Blood Disorders
  • Genetic Factors
  • AML Symptoms
  • Increased Bruising or Bleeding
  • Repeated or Frequent Infection
  • Anemia
  • AML Diagnosis
  • Full Blood Count
  • Bone Marrow Examination
  • Other Tests

4. TREATMENT OVERVIEW

  • Chemotherapy - The First-Line Treatment for AML
  • Induction Therapy
  • Post Remission or Consolidation Therapy
  • Hematopoietic Stem Cell Transplantation
  • Treatment for Relapsed AML
  • Maintenance
  • Side-Effects of AML Treatment
  • Effects on Bone Marrow, Platelets, Red Cells, and White Cells
  • Other Common Side-Effects
    • Changes in Smell and Taste
    • Vomiting and Nausea
    • Changes in Bowel
    • Mucositis
    • Loss of Hair
    • Loss in Fertility
    • Early Menopause
    • Fatigue
    • Body Image
  • Therapies to Complement AML Medical Treatment

5. FDA AND OTHER REGULATORY APPROVALS

  • Sunesis Pharmaceuticals Secures Orphan Drug Designation for Vosaroxin in EU
  • Cyclacel Pharmaceuticals Receives US Patent for Sapacitabine
  • Celator Pharmaceuticals Receives US Patent for CPX-351
  • Abbott Laboratories Receives US FDA Clearance for Vysis EGR1 FISH Probe Kit
  • Sunesis Pharmaceuticals Secures US FDA Fast Track Designation for Vosaroxin in Treating AML
  • US Patent and Trademark Office Approves New Patent for LOR-2040 Cancer Drug by Lorus Therapeutics
  • Sunesis Pharmaceuticals Secures European Patent for Vosaroxin Formulation
  • EpiCept Files for Marketing Approval of Ceplene in US
  • EntreMed's ENMD-2076 Obtains Orphan Drug Designation
  • Clavis Pharma Obtains Fast Track Designation for Elacytarabine by US FDA
  • EpiCept Corp. Launches Ceplene for AML in the UK
  • EpiCept Obtains Marketing Approval for Ceplene in Israel
  • Celgene Obtains Approval for VIDAZA from Health Canada
  • Gamida Cell-TEVA JV Obtains Orphan Drug Designation for StemEx from European Commission
  • Critical Outcome Technologies Obtains US Patent for AML Therapy

6. SELECT CLINICAL TRIALS

  • Akinion Pharmaceuticals Initiates Phase I/II Clinical Study of AKN-028
  • Celgene International Completes Phase I Study of Oral Azacitidine
  • Aprea Conducts Phase I/II Study of APR-246
  • Astellas Pharma and Ambit Biosciences Conduct Interim Results from Phase II Study of AC220
  • OXiGENE Publishes Preclinical Data on OXi4503
  • Pfizer's Mylotarg Fails second Phase III Trial in AML Treatment

7. RECENT INDUSTRY ACTIVITY

  • Cyclacel and Daiichi-Sankyo Amends License Agreement for Sapacitabine Drug
  • Bristol-Myers Squibb Signs Worldwide License Contract with Innate Pharma
  • Cell Therapeutics Signs Co-Development cum Licensing Deal with Chroma Therapeutics for Tosedostat
  • Supergen Enters into Merger Agreement with Astex Therapeutics
  • Celator® Pharmaceuticals Extends Research Agreement with Cephalon
  • Skyline Diagnostics and TrovaGene Enter into Agreement
  • EpiCept and MEDA Ink Agreement
  • Astellas Acquires Development and Sale Rights for AC220 Leukemia Drug of Ambit Biosciences
  • Biovitrum and Karolinska Development to Establish Joint Venture
  • Ambit Biosciences Enters into Partnership with Astellas Pharma
  • ChemGenex Pharmaceuticals Inks Deal with Hospira
  • Celator Pharmaceuticals Enters into Partnership with Leukemia & Lymphoma Society
  • Genzyme Signs Agreement with Bayer
  • Tragara Pharmaceuticals and S*BIO Ink Licensing Agreement

8. FOCUS ON SELECT KEY PLAYERS

  • Ambit Biosciences Inc. (US)
  • Aprea AB (Sweden)
  • Astellas Pharma Inc. (Japan)
  • Astex Pharmaceuticals, Inc. (US)
  • Bio-Path Holdings, Inc. (US)
  • BioSante Pharmaceuticals, Inc. (US)
  • Celator Pharmaceuticals, Inc. (US)
  • Celgene Corp. (US)
  • Clavis Pharma ASA (Norway)
  • Cyclacel Pharmaceuticals, Inc. (US)
  • EpiCept Corp. (US)
  • Genzyme Corporation (US)
  • Lorus Therapeutics, Inc. (Canada)
  • Novartis AG (Switzerland)
  • Onconova Therapeutics, Inc. (US)
  • Sunesis Pharmaceuticals, Inc. (US)

9. GLOBAL MARKET PERSPECTIVE

    • Table 7: World Recent Past, Current and Future Analysis for Acute Myeloid Leukemia Therapeutics by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)
    • Table 8: World 10-Year Perspective for Acute Myeloid Leukemia Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2009, 2012 and 2018 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Overview
      • Select AML Drugs Awarded Orphan Drug Designation in the US
      • Select AML Drugs Awarded Fast Track Designation in the US
    • Statistical Findings
    • Table 9: US Market for Hospital Cancer Therapies (2004 and 2010): Percentage (include corresponding Graph/Chart)
      • US Leukemia Statistics
      • Leukemia Incidence Statistics
    • Table 10: Leukemia Cases in the US (2011): Percentage Share Breakdown of New Cases by Site (includes corresponding Graph/Chart)
    • Table 11: Leukemia Cases in the US by Affected Site: 2009 (includes corresponding Graph/Chart)
    • Table 12: Leukemia Cases in the US by Affected Site: 2011 (includes corresponding Graph/Chart)
      • Leukemia Mortality Statistics
    • Table 13: Leukemia Related Deaths in the US By Affected Site: 2009 (includes corresponding Graph/Chart)
    • Table 14: Leukemia Related Deaths in the US By Affected Site: 2011 (includes corresponding Graph/Chart)
    • Regulatory Approvals/Patents
    • Select Clinical Trials
    • Strategic Corporate Initiatives
    • Focus on Select Major Players
  • B. Market Analytics
    • Table 15: The US Recent Past, Current and Future Analysis for Acute Myeloid Leukemia Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

2. JAPAN

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Developments
    • Astellas Pharma Inc - A Major Player
  • B. Market Analytics
    • Table 16: Japanese Recent Past, Current and Future Analysis for Acute Myeloid Leukemia Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

3. EUROPE

  • A. Market Analysis
    • Overview
    • Select AML Drugs Awarded Orphan Drug Designation in Europe
    • Current and Future Analysis
    • Statistics
    • Table 17: European Population Statistics for the 65+ Age Group: 2011
    • Table 18: Cancer Incidence in Europe by Site (2009) (includes corresponding Graph/Chart)
    • Regulatory Approvals/Patents
    • Select Clinical Trails
    • Strategic Corporate Developments
    • Focus on Select Major Players
  • B. Market Analytics
    • Table 19: European Recent Past, Current and Future Analysis for Acute Myeloid Leukemia Therapeutics Market by Country/Region Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)
    • Table 20: European 10-Year Perspective for Acute Myeloid Leukemia Therapeutics by Country/Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2009, 2012 and 2018 (includes corresponding Graph/Chart)

3a. FRANCE

  • Market Analysis
    • Table 21: French Recent Past, Current and Future Analysis for Acute Myeloid Leukemia Therapeutics with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

3b. GERMANY

  • Market Analysis
    • Table 22: German Recent Past, Current and Future Analysis for Acute Myeloid Leukemia Therapeutics with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

3c. ITALY

  • Market Analysis
    • Table 23: Italian Recent Past, Current and Future Analysis for Acute Myeloid Leukemia Therapeutics with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

3d. THE UNITED KINGDOM

  • Market Analysis
    • Table 24: UK Recent Past, Current and Future Analysis for Acute Myeloid Leukemia Therapeutics with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

3e. REST OF EUROPE

  • Market Analysis
    • Table 25: Rest of Europe Recent Past, Current and Future Analysis for Acute Myeloid Leukemia Therapeutics with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

4. REST OF WORLD

  • A. Market Analysis
    • Current and Future Analysis
    • Regional Market Overview
      • Australia
      • Incidence Rates
      • Canada
    • Table 26: Estimated New Cancer Cases by Type/Site Among Canadian Men: 2010 (includes corresponding Graph/Chart)
    • Table 27: Estimated New Cancer Cases by Type/Site Among Canadian Women: 2010 (includes corresponding Graph/Chart)
    • Table 28: Estimated Cancer Deaths by Type/Site Among Canadian Men: 2010 (includes corresponding Graph/Chart)
    • Table 29: Estimated Cancer Deaths by Type/Site Among Canadian Women: 2010 (includes corresponding Graph/Chart)
      • Asia
    • Table 30: Cancer Incidence in Asia-Oceania by Site: 2009 (includes corresponding Graph/Chart)
    • Regulatory Approvals
    • Strategic Corporate Developments
    • Lorus therapeutics, Inc. (Canada) - A Key Player
  • B. Market Analytics
    • Table 31: Rest of World Recent Past, Current and Future Analysis for Acute Myeloid Leukemia Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top